Maplight Therapeutics Inc (MPLT) is trading up at $8.25 (+1.10%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Analyst price targets on MPLT
One firm's current price target on Maplight Therapeutics Inc: $21 — 155% above the current $8.25. Each is tracked to its date and scored the same way a member's call is.
- Morgan Stanley $9.9 → $21 by Jul 2027 Jul 27, 2026 via Investing.com · Morgan Stanley's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
Maplight Therapeutics Inc net income history (FY2024–FY2025)
| FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|
| Income statement | ||
| Operating income | −$82.9M | −$169.1M |
| Net income | −$77.6M | −$161.2M |
| EPS (diluted) | −$105.38 | −$18.56 |
| Balance sheet | ||
| Cash and equivalents | $38.3M | $46.7M |
| Total assets | $136.9M | $479.5M |
| Total liabilities | $21.7M | $21.1M |
| Shareholders' equity | −$193.6M | $458.4M |
| Cash flow | ||
| Operating cash flow | −$78.8M | −$138.1M |
| Capital expenditure | $770.0K | $473.0K |
| Free cash flow | −$79.6M | −$138.6M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$20.9M | −$22.8M | −$23.5M | −$30.7M | −$31.5M | −$83.4M | −$64.5M | −$63.5M |
| Net income | −$19.0M | −$21.2M | −$22.3M | −$29.8M | −$29.4M | −$79.5M | −$60.7M | −$60.2M |
| EPS (diluted) | −$25.08 | −$28.01 | −$29.33 | −$39.11 | −$37.18 | $87.06 | −$1.34 | −$1.32 |
| Balance sheet | ||||||||
| Cash and equivalents | — | $38.3M | — | — | $64.1M | $46.7M | $55.7M | $71.6M |
| Total assets | — | $136.9M | — | — | $257.2M | $479.5M | $418.8M | $368.3M |
| Total liabilities | — | $21.7M | — | — | $23.7M | $21.1M | $19.0M | $20.0M |
| Shareholders' equity | −$172.4M | −$193.6M | −$215.8M | −$245.1M | −$274.2M | $458.4M | $399.8M | $348.3M |
| Cash flow | ||||||||
| Operating cash flow | — | −$21.5M | −$25.6M | −$34.0M | −$31.8M | −$46.8M | −$51.2M | −$44.9M |
| Capital expenditure | — | $106.0K | — | — | $31.0K | $376.0K | $24.0K | $22.0K |
| Free cash flow | — | −$21.6M | — | — | −$31.8M | −$47.2M | −$51.2M | −$44.9M |
From Maplight Therapeutics Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Maplight Therapeutics Inc
- Headquarters
- Redwood City, California From SEC filings, Oct 2026
Recent News (6)
-
MapLight Therapeutics’ Kreitzer sells $96,024 in common stock
MapLight Therapeutics’ Kreitzer sells $96,024 in common stock
-
MapLight Therapeutics CMO Erin Foff sells $124,068 in stock
MapLight Therapeutics CMO Erin Foff sells $124,068 in stock
-
MapLight Therapeutics chief scientific officer sells $93,025 in shares
MapLight Therapeutics chief scientific officer sells $93,025 in shares
-
MapLight Therapeutics CAO sells $82,149 in shares
MapLight Therapeutics CAO sells $82,149 in shares
-
MapLight Therapeutics general counsel reports $72,881 stock sale
MapLight Therapeutics general counsel reports $72,881 stock sale
-
Morgan Stanley downgrades MapLight Therapeutics stock rating on trial results Morgan Stanley downgrades MapLight Therapeutics stock rating on trial results
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International